$NNVC
NANOVIRICIDES, INC. Stock $nnvc

$nnvc Overview Financials Valuation SEC Filings Company Website

2016 Q3 Form 10-Q Financial Statement

#000114420416134199 Filed on November 14, 2016

Income Statement

Concept	2016 Q3	2015 Q3
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$990.0K	$940.0K
YoY Change	5.32%	6.82%
% of Gross Profit
Research & Development	$1.452M	$1.282M
YoY Change	13.26%	58.06%
% of Gross Profit
Depreciation & Amortization	$163.3K	$161.6K
YoY Change	1.04%	214.83%
% of Gross Profit
Operating Expenses	$2.440M	$1.282M
YoY Change	90.35%	-24.01%
Operating Profit	-$2.440M
YoY Change
Interest Expense	$245.0K	$245.0K
YoY Change	0.0%	0.0%
% of Operating Profit
Other Income/Expense, Net	-$621.0K	$918.1K
YoY Change	-167.64%	-36.6%
Pretax Income	-$3.060M	-$1.307M
YoY Change	134.13%	-253.76%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$3.061M	-$1.307M
YoY Change	134.24%	446.68%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.05	-$0.02
Diluted Earnings Per Share	-$0.05	-$0.02
COMMON SHARES
Basic Shares Outstanding	58.18M shares	57.27M shares
Diluted Shares Outstanding	58.18M shares	57.27M shares

Balance Sheet

Concept	2016 Q3	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$21.91M	$29.48M
YoY Change	-25.68%	-28.31%
Cash & Equivalents	$21.91M	$29.48M
Short-Term Investments
Other Short-Term Assets	$210.0K	$160.0K
YoY Change	31.25%
Inventory
Prepaid Expenses	$207.6K	$163.5K
Receivables
Other Receivables
Total Short-Term Assets	$22.12M	$29.64M
YoY Change	-25.38%	-28.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.62M	$12.13M
YoY Change	-4.23%	101.98%
Goodwill
YoY Change
Intangibles	$389.4K	$397.7K
YoY Change	-2.08%	-2.07%
Long-Term Investments
YoY Change
Other Assets	$90.00K	$120.0K
YoY Change	-25.0%	-88.0%
Total Long-Term Assets	$12.10M	$12.66M
YoY Change	-4.39%	70.7%
TOTAL ASSETS
Total Short-Term Assets	$22.12M	$29.64M
Total Long-Term Assets	$12.10M	$12.66M
Total Assets	$34.22M	$42.30M
YoY Change	-19.1%	-13.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$930.0K	$800.0K
YoY Change	16.25%	63.27%
Accrued Expenses	$35.65K	$19.60K
YoY Change	81.93%	-92.62%
Deferred Revenue
YoY Change
Short-Term Debt	$5.690M	$0.00
YoY Change
Long-Term Debt Due	$5.689M
YoY Change
Total Short-Term Liabilities	$6.939M	$983.1K
YoY Change	605.82%	30.58%
LONG-TERM LIABILITIES
Long-Term Debt	$3.320M	$7.510M
YoY Change	-55.79%	-2.85%
Other Long-Term Liabilities	$3.740M	$3.090M
YoY Change	21.04%	-62.95%
Total Long-Term Liabilities	$7.059M	$10.60M
YoY Change	-33.44%	-7.29%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.939M	$983.1K
Total Long-Term Liabilities	$7.059M	$10.60M
Total Liabilities	$14.00M	$11.59M
YoY Change	20.8%	-4.95%
SHAREHOLDERS EQUITY
Retained Earnings	-$67.89M
YoY Change
Common Stock	$58.20K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$20.23M	$30.71M
YoY Change
Total Liabilities & Shareholders Equity	$34.22M	$42.30M
YoY Change	-19.09%	-13.71%

Cashflow Statement

Concept	2016 Q3	2015 Q3
OPERATING ACTIVITIES
Net Income	-$3.061M	-$1.307M
YoY Change	134.24%	446.68%
Depreciation, Depletion And Amortization	$163.3K	$161.6K
YoY Change	1.04%	214.83%
Cash From Operating Activities	-$2.225M	-$1.650M
YoY Change	34.84%	-2.94%
INVESTING ACTIVITIES
Capital Expenditures	$24.44K	$333.7K
YoY Change	-92.68%	-40.68%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$20.00K	-$330.0K
YoY Change	-93.94%	-41.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		0.000
YoY Change		-100.0%
NET CHANGE
Cash From Operating Activities	-$2.225M	-1.650M
Cash From Investing Activities	-20.00K	-330.0K
Cash From Financing Activities		0.000
Net Change In Cash	-$2.225M	-1.980M
YoY Change	12.36%	-144.8%
FREE CASH FLOW
Cash From Operating Activities	-$2.225M	-$1.650M
Capital Expenditures	$24.44K	$333.7K
Free Cash Flow	-$2.249M	-$1.984M
YoY Change	13.39%	-12.32%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	6841190	USD
CY2016Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	87810145	USD
CY2016Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	219458	USD
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	58179	USD
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	58202	USD
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-64824201	USD
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	23048214	USD
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	36633418	USD
CY2016Q2	us-gaap	Liabilities Liabilities	13585204	USD
CY2016Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	35649	USD
CY2016Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	35602	USD
CY2016Q3	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	658439	USD
CY2016Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	767454	USD
CY2016Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	96524	USD
CY2016Q2	us-gaap	Assets Assets	36633418	USD
CY2016Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	389400	USD
CY2016Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	391467	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	69554	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	67487	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	458954	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	458954	USD
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11621916	USD
CY2016Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2014102	USD
CY2016Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1850816	USD
CY2016Q2	us-gaap	Assets Current AssetsCurrent	24381643	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21912927	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24162185	USD
CY2016Q2	nnvc	Service Agreements ServiceAgreements	96026	USD
CY2016Q3	nnvc	Service Agreements ServiceAgreements	87348	USD
CY2016Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	5474737	USD
CY2016Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	269388	USD
CY2016Q3	us-gaap	Liabilities Liabilities	13997603	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-67885645	USD
CY2016Q3	us-gaap	Security Deposit SecurityDeposit	3515	USD
CY2016Q2	us-gaap	Security Deposit SecurityDeposit	3515	USD
CY2016Q3	us-gaap	Other Assets OtherAssets	90863	USD
CY2016Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	5688609	USD
CY2016Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	120123	USD
CY2016Q3	nnvc	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	13291	USD
CY2016Q3	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-11895	USD
CY2016Q3	nnvc	Common Stock Issued Upon Exercise Of Stock Options CommonStockIssuedUponExerciseOfStockOptions	0	USD
CY2015Q3	nnvc	Common Stock Issued Upon Exercise Of Stock Options CommonStockIssuedUponExerciseOfStockOptions	313	USD
CY2016Q3	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	38250	USD
CY2015Q3	us-gaap	Depreciation Depreciation	161606	USD
CY2016Q3	us-gaap	Depreciation Depreciation	163286	USD
CY2015Q3	us-gaap	Adjustment For Amortization AdjustmentForAmortization	2067	USD
CY2016Q3	us-gaap	Adjustment For Amortization AdjustmentForAmortization	2067	USD
CY2015Q3	nnvc	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	1487982	USD
CY2015Q3	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-50932	USD
CY2015Q3	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1653826	USD
CY2016Q3	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2224823	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1987490	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2249258	USD
CY2015Q3	us-gaap	Interest Paid InterestPaid	286667	USD
CY2016Q3	us-gaap	Interest Paid InterestPaid	286667	USD
CY2015Q3	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2016Q3	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31467748	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29480258	USD
CY2016Q2	us-gaap	Other Assets OtherAssets	99541	USD
CY2015Q3	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	41550	USD
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	20225066	USD
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	34222669	USD
CY2016Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	403462	USD
CY2015Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	333710	USD
CY2016Q3	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	47	USD
CY2015Q3	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-8920	USD
CY2015Q3	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-41667	USD
CY2016Q3	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-41668	USD
CY2016Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	207563	USD
CY2016Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	88048410	USD
CY2016Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	7996402	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	2440449	USD
CY2016Q3	us-gaap	Land Land	260000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	391467	USD
CY2016Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	203030	USD
CY2016Q3	us-gaap	Interest Payable Current InterestPayableCurrent	166667	USD
CY2016Q2	us-gaap	Interest Payable Current InterestPayableCurrent	166667	USD
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6938875	USD
CY2016Q2	us-gaap	Liabilities Current LiabilitiesCurrent	6744014	USD
CY2016Q3	nnvc	Deferred Interest Payable Noncurrent DeferredInterestPayableNoncurrent	124999	USD
CY2016Q2	nnvc	Deferred Interest Payable Noncurrent DeferredInterestPayableNoncurrent	166667	USD
CY2016Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	7058728	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1452137	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1282072	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	988312	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	942979	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2440449	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	14176	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8825	USD
CY2016Q3	us-gaap	Interest Expense InterestExpense	245000	USD
CY2015Q3	us-gaap	Interest Expense InterestExpense	245000	USD
CY2015Q3	nnvc	Discount On Convertible Debentures DiscountOnConvertibleDebentures	333710	USD
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2015Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1487982	USD
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58179949	shares
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	918097	USD
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57274315	shares
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1306954	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-3061444	USD
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58179949	shares
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57274315	shares
CY2016Q3	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	2000	USD
CY2016Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	24435	USD
CY2015Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	333664	USD
CY2016Q3	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	17148	USD
CY2015Q3	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	8745	USD
CY2016Q3	us-gaap	Business Acquisition Date Of Acquisition Agreement1 BusinessAcquisitionDateOfAcquisitionAgreement1	2005-05-12
CY2015Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5993823	shares
CY2016Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6633848	shares
CY2016Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2015Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2016Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.05
CY2015Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.02
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3061444	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1306954	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3061444	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1306954	USD
CY2016Q3	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
CY2015Q3	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.05
CY2015Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.02
CY2016Q2	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	9000000	USD
CY2016Q3	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	9000000	USD
CY2016Q2	nnvc	Office Equipment Gross OfficeEquipmentGross	46897	USD
CY2016Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	5607	USD
CY2016Q2	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	5302677	USD
CY2013Q3	nnvc	Warrants Issued WarrantsIssued	2945428	shares
CY2014Q1	nnvc	Warrants Issued WarrantsIssued	2479935	shares
CY2013Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2810071	shares
CY2014Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2479935	shares
CY2016Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	75000	shares
CY2016Q3	dei	Document Type DocumentType	10-Q
CY2016Q3	dei	Amendment Flag AmendmentFlag	false
CY2016Q3	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
CY2016Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2016Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2016Q3	dei	Entity Registrant Name EntityRegistrantName	NANOVIRICIDES, INC.
CY2016Q3	dei	Entity Central Index Key EntityCentralIndexKey	0001379006
CY2016Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2016Q3	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2016Q3	dei	Trading Symbol TradingSymbol	NNVC
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	58203000	shares
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	58202708	shares
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58202708	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	58179699	shares
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58179699	shares
CY2016Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q3	nnvc	Series Preferred Shares Issued During Period Employee Stock Compensation Value Issued SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued	182898	USD
CY2016Q3	nnvc	Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne	27000	USD
CY2016Q3	nnvc	Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services For August StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServicesForAugust	17148	USD
CY2016Q3	nnvc	Stock Issued For Payment Of Director Fees Value StockIssuedForPaymentOfDirectorFeesValue	11250	USD
CY2016Q3	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><strong>Note 1 - Organization and Nature of Business</strong></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">NanoViricides, Inc. was incorporated under the laws of the State of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Colorado</font> on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">July 25, 2000</font> as <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Edot-com.com, Inc.</font> which was organized for the purpose of conducting internet retail sales.  On April 1, 2005, Edot-com.com, Inc. was incorporated under the laws of the State of Nevada for the purpose of re-domiciling as a Nevada corporation.  On <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">May 12, 2005</font>, the corporations were merged and Edot-com.com, Inc., the Nevada corporation, became the surviving entity.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On June 1, 2005, Edot-com.com, Inc. (“ECMM”) acquired Nanoviricides, Inc., a privately owned Florida corporation (“NVI”), pursuant to an Agreement and Plan of Share Exchange (the “Exchange”).  Nanoviricides, Inc. was incorporated under the laws of the State of Florida on May 12, 2005.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Pursuant to the terms of the Exchange, ECMM acquired NVI in exchange for an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 80,000,000</font> newly issued shares of ECMM common stock resulting in an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100,000,000</font> shares of ECMM common stock issued and outstanding.  NVI then became a wholly-owned subsidiary of ECMM. The ECMM shares were issued to the NVI shareholders on a pro rata basis, on the basis of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,000</font> shares of the Company’s common stock for each share of NVI common stock held by such NVI shareholder at the time of the Exchange.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As a result of the Exchange transaction, the former NVI stockholders held approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 80</font>% of the voting capital stock of the Company immediately after the Exchange.  For financial accounting purposes, this acquisition was a reverse acquisition of ECMM by NVI, under the purchase method of accounting, and was treated as a recapitalization with NVI as the acquirer. Accordingly, the financial statements have been prepared to give retroactive effect to May 12, 2005 (date of inception), of the reverse acquisition completed on June 1, 2005, and represent the operations of NVI.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On June 28, 2005, NVI was merged into its parent ECMM and the separate corporate existence of NVI ceased.  Effective on the same date, Edot-com.com, Inc. changed its name to NanoViricides, Inc. and its stock symbol to “NNVC”, respectively.  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> NanoViricides,  Inc. (the “Company”), is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. NanoViricides is unique in the bio-pharma field in that it possesses its own state of the art facilities for the design, synthesis, analysis and characterization of the nanomedicines that we develop, as well as for production scale-up, and e-GMP-like production in quantities needed for human clinical trials. The biological studies such as the effectiveness, safety, bio-distribution and Pharmacokinetics/Pharmacodynamics on our drug candidates are performed by external collaborators and contract organizations.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We are a company with several drugs in various stages of early development. Our drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), to which we have the necessary exclusive licenses in perpetuity. The first agreement we executed with TheraCour on September 1, 2005, gave us an exclusive, worldwide license for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On February 15, 2010 the Company executed an Additional License Agreement with TheraCour.  Pursuant to the Additional License Agreement, the Company was granted exclusive licenses, in perpetuity, for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes.  As consideration for obtaining these exclusive licenses, we agreed to pay a onetime licensing fee equal to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,000,000</font> shares <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">(adjusted for the 3.5 to 1 reverse split)</font> of the Company’s Series A Convertible Preferred Stock (the “Series A Preferred Stock”).  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The Series A Preferred Stock is convertible, only upon sale or merger of the Company, or the sale of or license of substantially all of the Company’s intellectual property, into shares of the Company’s common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock. </font>  The Series A Preferred Stock has a preferred voting preference at the rate of nine votes per share. The Series A Preferred Stock do not contain any rights to dividends, have no liquidation preference, and are not to be amended without the Holder’s approval. The 2,000,000 shares were valued at the par value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,000</font>.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q3	dei	Entity Incorporation State Country Name EntityIncorporationStateCountryName	Colorado
CY2016Q3	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2000-07-25
CY2016Q3	us-gaap	Business Acquisition Name Of Acquired Entity BusinessAcquisitionNameOfAcquiredEntity	Edot-com.com, Inc.
CY2016Q3	us-gaap	Debt Instrument Redemption Description DebtInstrumentRedemptionDescription	the Company, at its sole option, shall have the right, but not the obligation, to repurchase the Debenture at any time prior to the Maturity Date (the Redemption). If the Company intends to repurchase the Debenture, and if the closing bid price of the Common Stock is greater than $5.25 on the Redemption Date, unless the Holder, on or prior to the Redemption Date, elects to receive the Redemption Payment, as that term is defined herein, the Company shall pay to the Holder: (i) 952,381 shares of Common Stock in consideration of the exchange of the principal amount of the Debenture; and (ii) any and all accrued coupon interest. If on or prior to the Redemption Date, the Holder elects to receive the Redemption Payment, or the closing bid price of the Common Stock is less than $5.25, the Company shall issue to the Holder: (i) the principal amount of the Debenture; (ii) any accrued coupon interest; (iii) additional interest of 7% per annum for the period from the date of issuance of the Debenture to the Redemption Date; and (iv) warrants to purchase 619,048 shares of Common Stock which shall expire in three years from the date of issuance at an exercise price of $6.05 per share of Common Stock (the Redemption Warrants, and collectively with (i) (iv), the Redemption Payment). The Company shall use its best efforts to register the shares underlying the Redemption Warrants under a shelf registration statement, provided same is available to the Company, in accordance with the provisions of the Securities Act.
CY2016Q3	us-gaap	Related Party Transaction Description Of Transaction RelatedPartyTransactionDescriptionOfTransaction	charge its costs (direct and indirect) plus no more than 30% of direct costs
CY2016Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.25
CY2016Q3	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	172864	USD
CY2015Q3	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-30975	USD
CY2016Q3	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-109015	USD
CY2015Q3	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	422091	USD
CY2016Q3	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-8678	USD
CY2015Q3	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-19449	USD
CY2016Q3	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	34264	USD

Files In Submission

Name	View Source	Status
0001144204-16-134199-index-headers.html	Edgar Link	pending
0001144204-16-134199-index.html	Edgar Link	pending
0001144204-16-134199.txt	Edgar Link	pending
0001144204-16-134199-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
nnvc-20160930.xml	Edgar Link	completed
nnvc-20160930.xsd	Edgar Link	pending
nnvc-20160930_cal.xml	Edgar Link	unprocessable
nnvc-20160930_def.xml	Edgar Link	unprocessable
nnvc-20160930_lab.xml	Edgar Link	unprocessable
nnvc-20160930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v452122_10q.htm	Edgar Link	pending
v452122_ex31-1.htm	Edgar Link	pending
v452122_ex31-2.htm	Edgar Link	pending
v452122_ex32-1.htm	Edgar Link	pending
v452122_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NNVC
NANOVIRICIDES, INC. Stock $nnvc

2016 Q3 Form 10-Q Financial Statement

#000114420416134199 Filed on November 14, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NNVC NANOVIRICIDES, INC. Stock $nnvc

2016 Q3 Form 10-Q Financial Statement

#000114420416134199 Filed on November 14, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NNVC
NANOVIRICIDES, INC. Stock $nnvc